智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司收到了国家药品监督管理局(简称“国家药监局”)颁发的比索洛尔氨氯地平片(规格：富马酸比索洛尔5mg与苯磺酸氨氯地平(按C₂₀H₂₅ClN₂O₅计)5mg)《药品注册证书》(证书编号：2025S01866)，批准该药品生产。
由默克研制的比索洛尔氨氯地平片，最早于2010年10月通过互认程序获批上市，参照成员国为匈牙利，2021年5月，经国家药品监督管理局批准，比索洛尔氨氯地平片在国内获批上市。本品作为高血压治疗的替代疗法，用于目前同时服用与复方制剂剂量相同的单药且血压控制良好的患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.